Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234429 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12GRIK1GRIK2 | |
| SCHEMBL293294 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12GRIK1GRIK2 | |
| SCHEMBL295878 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12GRIK1GRIK2 | |
| SCHEMBL295880 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12GRIK1GRIK2 | |
| SCHEMBL2234435 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12GRIK1GRIK2 | |
| SCHEMBL8090761 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL9978358 | 0.82 | ALDH1A1 (0.34) | GRIK1GRIK2CYP2C9 | |
| SCHEMBL9978359 | 0.82 | ALDH1A1 (0.34) | GRIK1GRIK2CYP2C9 | |
| SCHEMBL9978356 | 0.82 | ALDH1A1 (0.34) | GRIK1GRIK2CYP2C9 | |
| SCHEMBL9978585 | 0.82 | ALDH1A1 (0.34) | GRIK1GRIK2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921080-B2 | Pig liver esterases | DSM IP ASSETS B.V. (NL) | 2014-12-30 | — | — | US | claimed |
| WO-2012021446-A2 | PROCESS FOR PREPARING ALISKIREN AND ITS INTERMEDIATES | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-02-16 | — | — | WO | claimed |
| EP-2421962-B1 | IMPROVED PIG LIVER ESTERASES | DPX HOLDINGS BV (NL) | 2018-08-29 | — | — | EP | disclosed |
| EP-2171061-B1 | PREPARATION OF AN ESTERASE | DPX HOLDINGS BV (NL) | 2017-09-27 | — | — | EP | disclosed |
| US-9309503-B2 | Preparation of an esterase | DPX HOLDINGS B.V. (NL) | 2016-04-12 | — | — | US | disclosed |
| CN-101351548-B | There is the polypeptide of esterase activity and the esterase of restructuring and uses thereof | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO.KG (AT) | 2015-08-19 | — | — | CN | disclosed |
| US-8921080-B2 | Pig liver esterases | DSM IP ASSETS B.V. (NL) | 2014-12-30 | — | — | US | disclosed |
| US-8642312-B2 | Polypeptide having esterase activity and recombinant esterase and use thereof | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2014-02-04 | — | — | US | disclosed |
| US-20130310577-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP ASSETS B.V. (NL) | 2013-11-21 | — | — | US | disclosed |
| US-8563279-B2 | Convergent synthesis of renin inhibitors and intermediates useful therein | DSM IP ASSETS B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| EP-2225200-B1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP ASSETS BV (NL) | 2013-10-16 | — | — | EP | disclosed |
| WO-2007073845-A2 | POLYPEPTIDE HAVING ESTERASE ACTIVITY AND RECOMBINANT ESTERASE AND USE THEREOF | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007073847-A1 | NOVEL POLYPEPTIDE HAVING ESTERASE ACTIVITY AND RECOMBINANT ESTERASE AND USE THEREOF | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007073846-A1 | METHOD FOR PREPARING ENANTIOMERICALLY ENRICHED 2-ALKYL-5-HALOPENT-4-ENECARBOXYLIC ACIDS AND -CARBOXYLIC ESTERS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-07-05 | — | — | WO | disclosed |
| EP-1801094-A1 | METHOD FOR PRODUCING (4E)-5-CHLORO-2-ISOPROPYL-4-PENTENOATE AND OPTICALLY ACTIVE SUBSTANCE THEREOF | Asahi Glass Company, Limited (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-7232925-B2 | Process for producing (4E)-5-chloro-2-isopropyl-4-pentenoate and optically active form thereof | ASAHI GLASS COMPANY, LIMITED (JP) | 2007-06-19 | — | — | US | disclosed |
| US-7232925-B2 | Process for producing (4E)-5-chloro-2-isopropyl-4-pentenoate and optically active form thereof | ASAHI GLASS COMPANY, LIMITED (JP) | 2007-06-19 | — | — | US | disclosed |
| WO-2007028714-A2 | METHOD FOR PRODUCING 2-SUBSTITUTED CARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | WO | disclosed |
| WO-2006033705-A1 | PROCESS FOR THE PRODUCTION OF (S)-5-CHLORO-2-ISOPROPYLPENT-4-ENOIC ACID ESTERS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1626093-A1 | Process for the production of (S)-5-chloro-2-isopropylpent-4-enoic acid esters | DOW GLOBAL TECHNOLOGIES INC. (US) | 2006-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310577-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | REN, ACE, AGT | SMN1; SMN2 4654/4885CA14 412/4885CA12 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.